Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - Blake Insomnia Therapeutics, Inc. | bkit_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
FORM 8-K |
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1933
|
February 6, 2017 |
|
Date of Report (date of Earliest Event Reported) |
|
Blake Insomnia Therapeutics, Inc. |
|
(Name of small business issuer in its charter) |
|
Nevada |
|
3949 |
|
46-0780380 |
|
(State or other Employer jurisdiction of Identification incorporation or organization) |
|
(Primary Standard Industrial Classification Code Number) |
|
(I.R.S. Number) |
Birger Jan Olsen
244 5th Avenue Suite A-154
N.Y. 10001 New York
USA
Phone: +1 (646) 453-4912
(Address and telephone number of registrant's principal executive offices and principal place of business)
Birger Jan Olsen
244 5th Avenue Suite A-154
N.Y. 10001 New York
USA
Phone: +1 (646) 453-4912
(Name, address, and telephone number of agent for service)
Please send a copy of all correspondence to:
Jillian Ivey Sidoti, Esq
PHONE 323-799-1342
jillian@crowdfundinglawyers.net
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
| |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
| |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
| |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On February 6, 2017, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Blake Insomnia Therapeutics, Inc. | |||
| Date: February 6, 2017 | By: | /s/ Birger Jan Olsen | |
|
|
|
Birger Jan Olsen |
|
| Chief Executive Officer | |||
|
3 |